GSK839

Class: Tryptophan synthase inhibitor

Details of activity:	Active against Mycobacterium tuberculosis; tryptophan synthase inhibitor (TrpAB inhibitor)
Description:	Synthetic compound; a tetrazole benzene sulfonamide
Institute where first reported:	GlaxoSmithKline
Highest developmental phase:	Preclinical
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	C1=CC(=CC=C1C2=NN(CC3=CC=C(C=N3)F)N=N2)S(=O)(=O)NCCO
Isomeric SMILES:	C1=CC(=CC=C1C2=NN(N=N2)CC3=NC=C(C=C3)F)S(=O)(=O)NCCO
InChI:	InChI=1S/C15H15FN6O3S/c16-12-3-4-13(17-9-12)10-22-20-15(19-21-22)11-1-5-14(6-2-11)26(24,25)18-7-8-23/h1-6,9,18,23H,7-8,10H2
InChI Key:	ZADGDPAVPJLDBU-UHFFFAOYSA-N

External links:
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/137499806
Main Source:	https://www.newtbdrugs.org/pipeline/compound/gsk839